Acumen plans presentation of Phase 2 sabirnetug trial baseline data at CTAD
ABOS•Acumen Pharmaceuticals plans to present three posters on its Phase 2 ALTITUDE-AD trial of sabirnetug at the Clinical Trials on Alzheimer’s Disease conference in Boston on Nov. 16-17, 2026.
1. Three posters planned
Acumen Pharmaceuticals will present three posters on its Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease conference in Boston. Scheduled for Nov. 16-17, the presentations will cover preliminary participant baseline characteristics, treatment expectations and motivations, and care partners’ experiences. The conference runs Nov. 16-19, 2026.
